Renal cell carcinoma future or investigational therapies: Difference between revisions
No edit summary |
(Mahshid) |
||
Line 15: | Line 15: | ||
[[Category:Nephrology]] | [[Category:Nephrology]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Nephrology]] | |||
[[Category:Surgery]] |
Latest revision as of 15:22, 27 November 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Renal cell carcinoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Renal cell carcinoma future or investigational therapies On the Web |
American Roentgen Ray Society Images of Renal cell carcinoma future or investigational therapies |
FDA on Renal cell carcinoma future or investigational therapies |
CDC on Renal cell carcinoma future or investigational therapies |
Renal cell carcinoma future or investigational therapies in the news |
Blogs on Renal cell carcinoma future or investigational therapies |
Risk calculators and risk factors for Renal cell carcinoma future or investigational therapies |
Future or Investigational Therapies
Vaccine
In November 2006, it was announced that a vaccine had been developed and tested with very promising results.(See [2]) The new vaccine, called TroVax, works by harnessing the patient's own immune system to fight the disease. Oxford BioMedica[3]. Further vaccine trials are underway.